ADC Therapeutics SA ADCT

About ADC Therapeutics SA (ADCT): stock profile, AI score and financials

ADC Therapeutics SA (ADCT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ADCT at 23.2/100 on a composite quality score built from its SEC filings, placing it at rank #2,691 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (6.2) and profitability (6.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ADC Therapeutics SA reports quarterly revenue of $19.2M, net income of $-16.6M, an operating margin of -132.0%. Top institutional holders of ADCT by reported 13-F value include Nantahala Capital Management, Redmile Group, TCG Crossover Management, based on the most recent SEC filings. ADCT trades on the NYSE exchange and files with the SEC under CIK 1771910. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ADCT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ADC Therapeutics SA directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1771910 →